title: Molecular genetics of cancer susceptibility.
abstract: Studies on the role of genetically polymorphic enzymes like cytochrome P450 1A1, arylamine N-acetyltransferase 2 or glutathione S-transferase M1 as cancer susceptibility factors date back more than 20 years, and some associations have been confirmed in several studies and meta-analyses. Overall, the extent of risk modulation due to these polymorphisms is only moderate but remains epidemiologically relevant. The role of some of these polymorphisms in human health may even be ambiguous: rapid acetylation, for example, protects from urinary bladder cancer but appears to increase the risk of laryngeal, lung and colon cancer. The first genetic polymorphisms in xenobiotics transporters such as P-gp (MDR1) and MRP2 have recently been identified. These polymorphisms may have great impact as cancer susceptibility factors as well as factors modulating the outcome of cancer treatment. Enzymes involved in generation or detoxification of reactive oxygen species also have to be considered; one of these enzymes, myeloperoxidase, constitutes a relatively strong lung cancer risk factor, as confirmed in 4 independent studies. Other genes, including those coding for DNA repair enzymes, signal transduction and cell growth regulation, may ultimately prove more important than the metabolic enzymes as cancer susceptibility factors. Study designs in molecular genetic epidemiology are evolving; large ongoing prospective trials increasingly allow confirmatory nested case control studies to be performed. However, carefully controlled, large case-control studies will remain the mainstay in molecular genetic epidemiology. Molecular genetic epidemiological evaluation of response to chemoprevention as well as response to the adverse events of cancer chemotherapy are likely to provide results that may be useful for individualized prevention and treatment in the near future. Since routine genotyping of all persons is now feasible, something like a genotype passport may soon become reality, and molecular and clinical epidemiological studies will have to provide the basis for understanding how to use genotype data for the benefit of the population.
authors.affiliation: Institute of Clinical Pharmacology, University Medical Center Charité, Humboldt University of Berlin, Berlin, Germany. jurgen.brockmoller@charite.de
authors.forename: J
authors.initials: J
authors.lastname: Brockmöller
authors.forename: I
authors.initials: I
authors.lastname: Cascorbi
authors.forename: S
authors.initials: S
authors.lastname: Henning
authors.forename: C
authors.initials: C
authors.lastname: Meisel
authors.forename: I
authors.initials: I
authors.lastname: Roots
mesh_terms: D000818:Animals; D006801:Humans; D008967:Molecular Biology; D009369:Neoplasms / Q000201:enzymology / Q000235:genetics*; D012307:Risk Factors